Alligator Bioscience AB (publ) (STO: ATORX)

Sweden flag Sweden · Delayed Price · Currency is SEK
1.320
+0.056 (4.43%)
Aug 30, 2024, 5:29 PM CET
220.39%
Market Cap 1.00B
Revenue 45.95M
Net Income -234.30M
Shares Out 758.04M
EPS -0.35
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 718,991
Open 1.272
Previous Close 1.264
Day's Range 1.270 - 1.330
52-Week Range 0.340 - 1.568
Beta 1.41
Analysts n/a
Price Target n/a
Earnings Date Oct 24, 2024

About Alligator Bioscience AB

Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Sweden. The company’s product portfolio includes Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 2 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage. It also offers ALG.APV-527, a bispecific antibody t... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 51
Stock Exchange Nasdaq Stockholm
Ticker Symbol ATORX
Full Company Profile

News

There is no news available yet.